Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 16;9(3):306-310.
doi: 10.1515/dx-2022-0042. eCollection 2022 Aug 1.

Homocysteine in coronavirus disease (COVID-19): a systematic literature review

Giovanni Carpenè  1 , Davide Negrini  1 , Brandon M Henry  2 , Martina Montagnana  1 , Giuseppe Lippi  1
Affiliations
Free article

Homocysteine in coronavirus disease (COVID-19): a systematic literature review

Giovanni Carpenè et al. Diagnosis (Berl). .
Free article

Abstract

Objectives: Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disorder characterized by a sustained prothrombotic state. Since homocysteine is a potential biomarker of thrombotic diseases, the aim of this article is to provide an updated overview on the possible role played by hyperhomocysteinemia in influencing an unfavorable COVID-19 progression.

Methods: We carried out an electronic search in Medline (PubMed interface) using the keywords ("COVID-19" OR "SARS-CoV-2") AND "homocysteine", between 2019 and the present time, with no language restrictions, to identify all articles which explored the concentration of homocysteine in COVID-19 patients with or without unfavorable disease progression.

Results: Three studies, totaling 694 hospitalized COVID-19 patients, were included in our systematic review. Overall, the differences between the mean homocysteine values in non-severe vs. severe COVID-19 patients were always positive (i.e., 15.1%, 24.1% and 22.8%, generating a positive weight mean difference of 1.75 μmol/L (95%CI, 1.26-2.25 μmol/L; p=0.011), which translates into a cumulative difference of approximately ∼1.2 μmol/L.

Conclusions: Despite the limited evidence that has been garnered so far, increased homocysteine ​​levels may be a potentially useful marker for predicting the risk of unfavorable progression in patients with COVID-19.

Keywords: COVID-19; SARS-CoV-2; homocysteine; systematic literature review.

PubMed Disclaimer

References

    1. Lippi, G, Sanchis-Gomar, F, Henry, BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020;8:497.
    1. Lippi, G, Sanchis-Gomar, F, Henry, BM. COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon. Ann Transl Med 2020;8:693–93.
    1. Klok, FA, Kruip, MJ, van der Meer, NJ, Arbous, MS, Gommers, D, Kant, KM, et al.. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis Research 2020;191:148–50.
    1. Henry, BM, Vikse, J, Benoit, S, Favaloro, EJ, Lippi, G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020;507:167–73.
    1. Bikdeli, B, Madhavan, MV, Gupta, A, Jimenez, D, Burton, JR, Der Nigoghossian, C, et al.. Pharmacological agents targeting thromboinflammation in covid-19: review and implications for future research. Thromb Haemost 2020;120:1004–24.

Publication types

LinkOut - more resources